ADial Pharmaceuticals strongly believes that its drugs (with higher benefit ratios and effect-sizes) combined with appropriate positioning and strategic marketing initiatives, have the potential to reach large and untapped markets. This is why ADial has put together a winning team of experts to make it happen.

CLINICAL TEAM

• Bankole Johnson, DSc., M.D., Ph.D., M.Phil (Founder, President, Chairman) is one of the world’s leading authorities in addictive disorder research and is Chairman of the Department of Psychiatry and Neurobehavioral Sciences at the University of Virginia.
• Clinical Research Manager will be hired upon initial funding to manage the Clinical Research Organization selected to coordinate the phase III clinical trial.

EXECUTIVE TEAM

• Bankole Johnson, DSc., M.D., Ph.D., M.Phil (Founder, President, Chairman) is one of the world’s leading authorities in addictive disorder research and is Chairman of the Department of Psychiatry and Neurobehavioral Sciences at the University of Virginia.
• Patrick T. Long (Chief Executive Officer) has 35 years of commercialization and corporate development experience in the pharmaceutical industry.
• Michael Torok, PhD (Chief Operations Officer) is experienced in global clinical research and operations.

BUSINESS ADVISORY BOARD

• Kathleen M. Long, RPh (Strategic Marketing Consultant) is experienced in pharmaceutical marketing, positioning and payer strategies.
• Jim Sheffield, CFA (Corporate Finance Consultant) has 15 years of experience in international banking, corporate finance and new business development .

CORPORATE ADVISORY BOARD

ADial is developing an advisory board in order to provide insight into key developmental areas. In particular, ADial expects its board to consist of four people with expertise in chemistry, manufacturing, regulatory affairs and product development to add to its depth of knowledge of addiction. ADial has several people in mind for these positions.